12:00 AM
Apr 26, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BioMarin sales and marketing update

BioMarin launched its Firdapse amifampridine in Germany and the U.K. to treat Lambert Eaton Myasthenic Syndrome (LEMS). In February, BioMarin said Firdapse will...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >